MK-4280A, TRIFLURIDINE, COMBINATIONS, REGORAFENIB clinical trials

A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer (KEYFORM-007)

This study looks at a new drug combination, MK-4280A, for bowel cancer that has spread and has been treated before. It compares this new treatment to standard care to see if it helps people live longer and improves their quality of life.